At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver pathobiology are driving the rapid identification of new druggable targets across diverse indications. Read More
Hepatocellular carcinoma (HCC) remains a major cause of cancer death worldwide and, although early-stage disease can sometimes be cured by surgical resection and liver transplantation, advanced cases still respond poorly to current systemic treatments and immunotherapy. Read More
Moderna Inc. has announced an expanded collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of a potential vaccine against Bundibugyo Ebola virus (BDBV), a cause of Ebola virus disease. Read More
Deep Apple Therapeutics Inc. has divulged new alkylphenyl substituted compounds acting as gastric inhibitory polypeptide receptor (GIPR) antagonists potentially useful for the treatment of obesity and type 2 diabetes. Read More
Researchers from Pilatus Biosciences SA recently presented preclinical efficacy data for PLT-012, a humanized IgG4 antibody targeting CD36, in metabolic dysfunction-associated steatohepatitis (MASH) models. Read More
Laverock Therapeutics Ltd. has been awarded two new grants totaling in excess of £2.2 million (US$3 million) to support the next generation of its gene-control platform development, and expansion into additional nononcology therapeutics areas. Read More
Muna Therapeutics Aps has patented new dihydropyrrolopyrimidinone compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of osteoporosis, rheumatoid arthritis, systemic lupus erythematosus, type 2 diabetes, obesity, metabolic dysfunction-associated steatotic liver disease (MASLD; NAFLD), neurodegeneration and inflammatory bowel disease, among others. Read More
In the treatment of hepatocellular carcinoma (HCC), the long-term benefits of second-line tyrosine kinase inhibitors such as sorafenib are often limited by resistance mechanisms and adverse effects. The deubiquitinase ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) is upregulated in advanced HCC disease and has been linked to poor prognosis and treatment resistance. Read More
Army Medical University has identified new cyclic GMP-AMP synthase (MB21D1; cGAS)/STING pathway inhibitors potentially useful for the treatment of inflammatory disorders. Read More
Xtalpi Inc.’s strategic collaboration with Dovetree Medicines Unus Inc. has made substantial progress, with Xtalpi receiving the second payment under the agreement. Read More
